Roivant Sciences Ltd’s filing revealed that its Officer RICHARD PULIK acquired Company’s shares for reported $5.84 million on Dec 23 ’25. In the deal valued at $22.45 per share,260,000 shares were bought.
Then, RICHARD PULIK TRUST bought 146,731 shares, generating $3,285,755 in total proceeds.
Before that, ERIC VENKER bought 200,000 shares. Roivant Sciences Ltd shares valued at $4,490,540 were divested by the Officer at a price of $22.45 per share.
Citigroup initiated its Roivant Sciences Ltd [ROIV] rating to a Buy in a research note published on September 02, 2025; the price target was $16. Wolfe Research began covering ROIV with “an Outperform” recommendation on February 15, 2024. Piper Sandler started covering the stock on January 05, 2024. It rated ROIV as “an Overweight”.
Price Performance Review of ROIV
On Tuesday, Roivant Sciences Ltd [NASDAQ:ROIV] saw its stock fall -1.01% to $22.45. Over the last five days, the stock has lost -2.14%. Roivant Sciences Ltd shares have risen nearly 95.22% since the year began. Nevertheless, the stocks have risen 89.77% over the past one year. While a 52-week high of $23.47 was reached on 12/17/25, a 52-week low of $8.73 was recorded on 04/07/25.
Levels Of Support And Resistance For ROIV Stock
The 24-hour chart illustrates a support level at 22.19, which if violated will result in even more drops to 21.94. On the upside, there is a resistance level at 22.67. A further resistance level may holdings at 22.90.
How much short interest is there in Roivant Sciences Ltd?
A steep rise in short interest was recorded in Roivant Sciences Ltd stocks on 2025-11-28, dropping by -3.61 million shares to a total of 20.91 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-31 was 24.53 million shares. There was a decline of -17.28%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on December 12, 2023 when Deutsche Bank began covering the stock and recommended ‘”a Buy”‘ rating along with a $14 price target.
